1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Carbajo, R.J.
Mora, P.
Sanchez del Pino, M.M.
Perez-Paya, E.
Pineda-Lucena, A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
4
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
US
Proteins
PSFGEY
0867
1097-0134
71
1670
1685
10.1002/prot.21854
18076077
Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.
2008
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
3813.342
CELLULAR TUMOR ANTIGEN P53
TETRAMERIZATION DOMAIN, RESIDUES 326-356
YES
4
syn
polymer
TUMOR SUPPRESSOR P53, PHOSPHOPROTEIN P53, ANTIGEN NY-CO-13, P53
no
no
EYFFLKIRGRERFEMFRELNEALELKDAQAG
EYFFLKIRGRERFEMFRELNEALELKDAQAG
A,B,C,D
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
citation
citation_author
pdbx_nmr_spectrometer
repository
Initial release
Version format compliance
Version format compliance
Data collection
Database references
1
0
2007-08-28
1
1
2011-05-08
1
2
2011-07-13
1
3
2018-04-25
_citation.journal_id_ISSN
_citation.page_last
_citation.pdbx_database_id_DOI
_citation.title
_citation_author.name
_pdbx_nmr_spectrometer.model
SOLUTION STRUCTURE DETERMINATION OF A P53 MUTANT DIMERIZATION DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE
P53 TETRAMERIZATION DOMAIN CRYSTAL STRUCTURE
CRYSTAL STRUCTURE OF P53 TETRAMERIZATION DOMAIN
SOLUTION STRUCTURE OF THE C-TERMINAL NEGATIVE REGULATORY DOMAIN OF P53 IN A COMPLEX WITH CA2+-BOUND S100B(BB)
CRYSTAL STRUCTURE OF THE BRCT DOMAINS OF HUMAN 53BP1 BOUND TO THE P53 TUMOR SUPRESSOR
CDK2/CYCLINA IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
NMR SOLUTION STRUCTURE OF DESIGNED P53 DIMER
NMR STRUCTURE OF CBP BROMODOMAIN IN COMPLEX WITH P53 PEPTIDE
CRYSTAL STRUCTURE OF THE 53BP1 BRCT REGION COMPLEXED TOTUMOR SUPPRESSOR P53
STRUCTURE OF A SIR2 ENZYME BOUND TO AN ACETYLATED P53PEPTIDE
P53 (OLIGOMERIZATION DOMAIN) (NMR, MINIMIZED AVERAGE STRUCTURE)
P53 (OLIGOMERIZATION DOMAIN) (NMR, 35 STRUCTURES)
TUMOR ANTIGEN P53 (TETRAMERIZATION DOMAIN) ( P53TET) (NMR, MINIMIZED AVERAGE STRUCTURE)
TUMOR ANTIGEN P53 (TETRAMERIZATION DOMAIN) ( P53TET) (NMR, 19 STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES)
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAD STRUCTURES)
P53 CORE DOMAIN IN COMPLEX WITH DEOXYRIBONUCLEIC ACID
TUMOR SUPPRESSOR P53 COMPLEXED WITH DEOXYRIBONUCLEIC ACID
CRYSTAL STRUCTURE OF THE HUMAN P53 CORE DOMAIN MUTANT M133L/V203A/N239Y/N268D AT 1 .9 A RESOLUTION.
CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF THEMETHYLTRANSFERASE SET9 (ALSO KNOWN AS SET7 /9) WITH A P53PEPTIDE AND SAH
XENOPUS LAEVIS MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF HUMAN P53
MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53
P53-53BP2 COMPLEX
STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX I)
STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX IV)
STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX III)
STRUCTURAL BASIS OF DNA RECOGNITION BY P53 TETRAMERS(COMPLEX II)
P53N (FRAGMENT 33-60) BOUND TO RPA70N
HUMAN P53 CORE DOMAIN MUTANT M133L-V203A- N239Y-N268D-R273H
HUMAN P53 CORE DOMAIN MUTANT M133L-H168R- V203A-N239Y-N268D
HUMAN P53 CORE DOMAIN MUTANT M133L-V203A- N239Y-R249S-N268D
HUMAN P53 CORE DOMAIN MUTANT M133L-H168R- V203A-N239Y-R249S-N268D
HUMAN P53 CORE DOMAIN MUTANT T123A-M133L- H168R-V203A-N239Y-R249S-N268D
CRYSTAL STRUCTURE OF THE TRAF-LIKE DOMAIN OF HAUSP/USP7BOUND TO A P53 PEPTIDE
SOLUTION STRUCTURE OF HUMAN P53 DNA BINDING DOMAIN.
P53 TETRAMERIZATION DOMAIN WILD TYPE
P53 TETRAMERIZATION DOMAIN MUTANT Y327S T329G Q331G
HIGH RESOLUTION SOLUTION NMR STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI- DIMENSIONAL NMR (SAC STRUCTURES)
HELIX
DETERMINATION METHOD: AUTHOR PROVIDED.
PDBE
Y
PDBE
2006-08-08
REL
CHEMICAL SYNTHESIS
9606
HUMAN
HOMO SAPIENS
sample
ENGINEERED RESIDUE IN CHAIN A, THR 329 TO PHE
ENGINEERED RESIDUE IN CHAIN A, GLN 331 TO LYS
ENGINEERED RESIDUE IN CHAIN B, THR 329 TO PHE
ENGINEERED RESIDUE IN CHAIN B, GLN 331 TO LYS
ENGINEERED RESIDUE IN CHAIN C, THR 329 TO PHE
ENGINEERED RESIDUE IN CHAIN C, GLN 331 TO LYS
ENGINEERED RESIDUE IN CHAIN D, THR 329 TO PHE
ENGINEERED RESIDUE IN CHAIN D, GLN 331 TO LYS
NONE
TOTAL ENERGY
30
30
NOESY
TOCSY
7.2
pH
1.0
atm
300.0
K
CNS
5
5% D2O/95% WATER
BRUNGER,ADAMS,CLORE,DELANO,GROS, GROSSE- KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU,READ, RICE,SIMONSON,WARREN
refinement
CNS
structure solution
SPARKY
600
Bruker
AMX
GLU
326
n
1
GLU
326
A
TYR
327
n
2
TYR
327
A
PHE
328
n
3
PHE
328
A
PHE
329
n
4
PHE
329
A
LEU
330
n
5
LEU
330
A
LYS
331
n
6
LYS
331
A
ILE
332
n
7
ILE
332
A
ARG
333
n
8
ARG
333
A
GLY
334
n
9
GLY
334
A
ARG
335
n
10
ARG
335
A
GLU
336
n
11
GLU
336
A
ARG
337
n
12
ARG
337
A
PHE
338
n
13
PHE
338
A
GLU
339
n
14
GLU
339
A
MET
340
n
15
MET
340
A
PHE
341
n
16
PHE
341
A
ARG
342
n
17
ARG
342
A
GLU
343
n
18
GLU
343
A
LEU
344
n
19
LEU
344
A
ASN
345
n
20
ASN
345
A
GLU
346
n
21
GLU
346
A
ALA
347
n
22
ALA
347
A
LEU
348
n
23
LEU
348
A
GLU
349
n
24
GLU
349
A
LEU
350
n
25
LEU
350
A
LYS
351
n
26
LYS
351
A
ASP
352
n
27
ASP
352
A
ALA
353
n
28
ALA
353
A
GLN
354
n
29
GLN
354
A
ALA
355
n
30
ALA
355
A
GLY
356
n
31
GLY
356
A
GLU
326
n
1
GLU
326
B
TYR
327
n
2
TYR
327
B
PHE
328
n
3
PHE
328
B
PHE
329
n
4
PHE
329
B
LEU
330
n
5
LEU
330
B
LYS
331
n
6
LYS
331
B
ILE
332
n
7
ILE
332
B
ARG
333
n
8
ARG
333
B
GLY
334
n
9
GLY
334
B
ARG
335
n
10
ARG
335
B
GLU
336
n
11
GLU
336
B
ARG
337
n
12
ARG
337
B
PHE
338
n
13
PHE
338
B
GLU
339
n
14
GLU
339
B
MET
340
n
15
MET
340
B
PHE
341
n
16
PHE
341
B
ARG
342
n
17
ARG
342
B
GLU
343
n
18
GLU
343
B
LEU
344
n
19
LEU
344
B
ASN
345
n
20
ASN
345
B
GLU
346
n
21
GLU
346
B
ALA
347
n
22
ALA
347
B
LEU
348
n
23
LEU
348
B
GLU
349
n
24
GLU
349
B
LEU
350
n
25
LEU
350
B
LYS
351
n
26
LYS
351
B
ASP
352
n
27
ASP
352
B
ALA
353
n
28
ALA
353
B
GLN
354
n
29
GLN
354
B
ALA
355
n
30
ALA
355
B
GLY
356
n
31
GLY
356
B
GLU
326
n
1
GLU
326
C
TYR
327
n
2
TYR
327
C
PHE
328
n
3
PHE
328
C
PHE
329
n
4
PHE
329
C
LEU
330
n
5
LEU
330
C
LYS
331
n
6
LYS
331
C
ILE
332
n
7
ILE
332
C
ARG
333
n
8
ARG
333
C
GLY
334
n
9
GLY
334
C
ARG
335
n
10
ARG
335
C
GLU
336
n
11
GLU
336
C
ARG
337
n
12
ARG
337
C
PHE
338
n
13
PHE
338
C
GLU
339
n
14
GLU
339
C
MET
340
n
15
MET
340
C
PHE
341
n
16
PHE
341
C
ARG
342
n
17
ARG
342
C
GLU
343
n
18
GLU
343
C
LEU
344
n
19
LEU
344
C
ASN
345
n
20
ASN
345
C
GLU
346
n
21
GLU
346
C
ALA
347
n
22
ALA
347
C
LEU
348
n
23
LEU
348
C
GLU
349
n
24
GLU
349
C
LEU
350
n
25
LEU
350
C
LYS
351
n
26
LYS
351
C
ASP
352
n
27
ASP
352
C
ALA
353
n
28
ALA
353
C
GLN
354
n
29
GLN
354
C
ALA
355
n
30
ALA
355
C
GLY
356
n
31
GLY
356
C
GLU
326
n
1
GLU
326
D
TYR
327
n
2
TYR
327
D
PHE
328
n
3
PHE
328
D
PHE
329
n
4
PHE
329
D
LEU
330
n
5
LEU
330
D
LYS
331
n
6
LYS
331
D
ILE
332
n
7
ILE
332
D
ARG
333
n
8
ARG
333
D
GLY
334
n
9
GLY
334
D
ARG
335
n
10
ARG
335
D
GLU
336
n
11
GLU
336
D
ARG
337
n
12
ARG
337
D
PHE
338
n
13
PHE
338
D
GLU
339
n
14
GLU
339
D
MET
340
n
15
MET
340
D
PHE
341
n
16
PHE
341
D
ARG
342
n
17
ARG
342
D
GLU
343
n
18
GLU
343
D
LEU
344
n
19
LEU
344
D
ASN
345
n
20
ASN
345
D
GLU
346
n
21
GLU
346
D
ALA
347
n
22
ALA
347
D
LEU
348
n
23
LEU
348
D
GLU
349
n
24
GLU
349
D
LEU
350
n
25
LEU
350
D
LYS
351
n
26
LYS
351
D
ASP
352
n
27
ASP
352
D
ALA
353
n
28
ALA
353
D
GLN
354
n
29
GLN
354
D
ALA
355
n
30
ALA
355
D
GLY
356
n
31
GLY
356
D
author_defined_assembly
4
tetrameric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
ILE
332
A
N
ILE
7
B
O
PHE
328
B
O
PHE
3
C
N
ILE
332
C
N
ILE
7
D
O
PHE
328
D
O
PHE
3
1
A
ALA
355
-93.46
-62.29
1
B
TYR
327
61.09
112.55
1
D
ARG
333
-98.31
31.38
2
A
ARG
333
-100.84
77.09
2
B
ARG
333
-98.65
31.29
2
B
ALA
355
-68.01
-72.55
2
C
ARG
333
-98.50
30.92
2
D
TYR
327
60.69
111.10
2
D
ALA
355
-100.61
-63.02
3
A
TYR
327
60.84
110.60
3
B
TYR
327
60.10
106.76
3
C
ARG
333
-98.47
34.26
3
C
ALA
355
-100.60
-67.29
4
B
ARG
333
-97.43
37.23
4
D
ARG
333
-98.30
35.64
5
A
ARG
333
-98.51
31.12
5
B
TYR
327
60.76
111.29
5
C
TYR
327
62.06
150.68
5
C
LYS
331
-67.57
97.28
5
C
ARG
333
-92.36
48.86
5
D
TYR
327
60.21
106.96
5
D
ARG
333
-98.63
31.09
6
A
PHE
328
-151.39
89.48
6
C
ARG
333
-98.36
33.86
6
D
TYR
327
60.72
111.23
7
A
TYR
327
61.13
112.64
7
A
ARG
333
-98.59
33.36
7
B
LEU
330
-164.41
104.85
7
B
ARG
333
-98.53
32.65
7
C
TYR
327
60.62
84.33
8
A
ARG
333
-98.71
31.12
8
C
TYR
327
63.29
123.30
8
D
TYR
327
59.98
106.50
8
D
ARG
333
-104.78
74.90
9
A
TYR
327
60.42
97.46
9
A
ALA
355
-123.17
-57.49
9
B
TYR
327
60.37
103.80
9
B
ARG
333
-93.53
47.52
9
C
TYR
327
61.16
112.77
9
C
ARG
333
-98.29
33.60
9
D
TYR
327
60.51
110.90
10
B
TYR
327
60.88
111.76
10
B
ARG
333
-92.94
48.04
10
B
ALA
355
-103.69
-69.39
10
C
TYR
327
62.84
120.26
10
C
ALA
355
-105.22
-68.81
10
D
ARG
333
-99.69
34.35
11
A
TYR
327
61.40
113.81
11
B
TYR
327
61.45
116.79
11
C
TYR
327
63.16
123.04
11
C
ARG
333
-98.78
30.95
11
D
TYR
327
63.71
137.17
11
D
ARG
333
-95.84
42.44
12
A
ARG
333
-98.60
31.11
12
B
TYR
327
61.17
112.68
12
B
ARG
333
-98.65
32.40
12
C
LYS
331
-68.06
84.06
12
C
ARG
333
-98.35
35.60
12
D
ARG
333
-98.57
31.85
12
D
ALA
355
-98.40
35.11
13
A
TYR
327
61.35
113.78
13
A
ARG
333
-97.45
37.77
13
B
TYR
327
60.33
96.89
13
C
TYR
327
60.41
104.01
13
D
TYR
327
60.85
111.91
14
A
TYR
327
61.14
112.42
14
B
TYR
327
60.78
111.07
14
B
LYS
331
-66.85
83.67
14
C
TYR
327
61.36
113.65
14
C
ARG
333
-103.53
76.80
14
D
LEU
330
-161.77
107.32
14
D
ARG
333
-98.66
35.40
15
A
LEU
330
-161.62
118.49
15
B
ARG
333
-98.60
32.50
15
B
ALA
355
-98.75
33.50
15
C
TYR
327
60.70
111.70
16
B
TYR
327
60.50
97.56
16
B
LYS
331
-66.43
84.94
16
B
ALA
355
-61.58
-75.14
16
C
ARG
333
-105.95
74.80
16
D
TYR
327
60.38
110.40
17
C
TYR
327
60.30
109.69
17
C
LYS
331
-66.54
83.47
17
C
ALA
355
-97.86
34.93
18
A
TYR
327
60.68
111.49
18
B
TYR
327
60.26
101.96
18
B
ARG
333
-98.40
33.26
18
C
TYR
327
60.53
110.72
18
C
ARG
333
-90.94
51.20
18
C
ALA
355
-97.16
38.18
19
A
TYR
327
61.59
114.37
19
B
TYR
327
63.27
127.89
19
C
TYR
327
60.89
111.76
19
D
TYR
327
60.71
111.33
20
A
TYR
327
-171.17
105.72
20
A
ARG
333
-95.59
42.13
20
B
ARG
333
-92.37
48.87
20
C
ARG
333
-98.68
31.30
20
D
ARG
333
-94.51
44.54
21
A
ALA
355
-89.95
-71.16
21
B
LEU
330
-164.95
118.22
21
B
ARG
333
-98.67
31.32
21
C
ARG
333
-98.53
30.63
21
C
ALA
355
-175.21
36.80
21
D
ARG
333
-96.83
39.42
22
A
TYR
327
63.27
141.49
22
B
TYR
327
60.27
89.17
22
B
ARG
333
-98.52
33.58
22
D
ARG
333
-99.13
31.60
23
A
TYR
327
60.67
111.12
23
A
ARG
333
-98.62
33.02
23
B
TYR
327
62.51
147.86
23
C
ARG
333
-98.54
33.68
23
C
ALA
355
-98.63
32.82
23
D
TYR
327
60.59
111.31
24
B
TYR
327
61.64
153.04
24
B
ARG
333
-105.94
72.95
24
C
ALA
355
-96.17
-68.17
24
D
TYR
327
61.04
112.39
24
D
ARG
333
-98.26
31.71
24
D
ALA
355
-98.10
36.64
25
B
TYR
327
60.29
108.71
25
B
ARG
333
-98.54
31.30
25
D
TYR
327
60.45
100.40
26
B
ARG
333
-100.25
78.31
26
C
TYR
327
60.91
111.65
26
C
LEU
330
-165.00
118.40
26
D
TYR
327
63.30
139.79
26
D
ALA
355
-92.32
-60.24
27
A
TYR
327
60.65
111.13
27
B
TYR
327
60.17
106.17
27
B
LEU
330
-160.03
103.08
27
B
ALA
355
-102.09
-66.66
27
C
TYR
327
60.78
111.56
27
C
ARG
333
-99.29
31.06
27
C
ALA
355
-97.56
36.96
28
A
ARG
333
-109.93
74.59
28
A
ALA
355
-85.81
-71.43
28
B
TYR
327
60.55
106.42
29
A
TYR
327
61.46
114.05
29
A
ARG
333
-98.69
32.48
29
B
ARG
333
-98.90
31.30
29
C
LEU
330
-170.92
124.38
29
D
TYR
327
60.77
111.47
29
D
ARG
333
-108.00
72.21
30
B
TYR
327
62.91
144.59
30
B
ARG
333
-98.89
31.24
30
C
ARG
333
-98.82
31.57
CELLULAR TUMOR ANTIGEN P53
p53 tetramerization domain mutant T329F Q331K
1
N
N
1
N
N
1
N
N
1
N
N
A
ARG
335
A
ARG
10
HELX_P
A
ALA
355
A
ALA
30
1
1
21
B
ARG
335
B
ARG
10
HELX_P
B
ALA
355
B
ALA
30
1
2
21
C
ARG
335
C
ARG
10
HELX_P
C
ALA
355
C
ALA
30
1
3
21
D
ARG
335
D
ARG
10
HELX_P
D
ALA
355
D
ALA
30
1
4
21
TRANSCRIPTION
P53, ZINC, ACTIVATOR, APOPTOSIS, WILD TYPE, CELL CYCLE, ACETYLATION, DNA-BINDING, POLYMORPHISM, TETRAMERIZATION DOMAIN, TRANSCRIPTION REGULATION, ANTI-ONCOGENE, NUCLEAR PROTEIN, PHOSPHORYLATION, LI-FRAUMENI SYNDROME, HOST-VIRUS INTERACTION, DISEASE MUTATION, ALTERNATIVE SPLICING, GLYCOPROTEIN, TRANSCRIPTION, METAL-BINDING
P53_HUMAN
UNP
1
P04637
326
356
2J10
326
356
P04637
A
1
1
31
326
356
2J10
326
356
P04637
B
1
1
31
326
356
2J10
326
356
P04637
C
1
1
31
326
356
2J10
326
356
P04637
D
1
1
31
1
THR
engineered mutation
PHE
329
2J10
A
P04637
UNP
329
4
1
GLN
engineered mutation
LYS
331
2J10
A
P04637
UNP
331
6
2
THR
engineered mutation
PHE
329
2J10
B
P04637
UNP
329
4
2
GLN
engineered mutation
LYS
331
2J10
B
P04637
UNP
331
6
3
THR
engineered mutation
PHE
329
2J10
C
P04637
UNP
329
4
3
GLN
engineered mutation
LYS
331
2J10
C
P04637
UNP
331
6
4
THR
engineered mutation
PHE
329
2J10
D
P04637
UNP
329
4
4
GLN
engineered mutation
LYS
331
2J10
D
P04637
UNP
331
6
2
2
anti-parallel
anti-parallel
A
PHE
328
A
PHE
3
A
ILE
332
A
ILE
7
B
PHE
328
B
PHE
3
B
ILE
332
B
ILE
7
C
PHE
328
C
PHE
3
C
ARG
333
C
ARG
8
D
TYR
327
D
TYR
2
D
ILE
332
D
ILE
7
1
P 1